Table 1 Indicators of quality of care that climacteric stage women receive in family medicine clinics

I. Health promotion

1. Counseling about climacteric stage and menopause in the last year

Number of climacteric stage women who received counseling about climacteric stage, menopause and self-care related activities by the family doctor or other health professionals, in the last year/Total number of women in the sample × 100

2. Nutritional counseling in the last year

Number of climacteric stage women who received nutritional counseling by the family doctor or other health professionals, in the last year/Total number of women in the sample × 100

3. Advice on regular leisure time physical activity in the last year

Number of climacteric stage women who received advice on regular leisure time physical activity by the family doctor or other health professionals, in the last year/Total number of women in the sample × 100

4. Smoke cessation counseling in the last year

Number of current smokers climacteric stage women who received smoke cessation counseling by the family doctor or other health professionals, in the last year/Total number of actively smoking women in the sample × 100

II. Screening

1. Deliberate search of climacteric symptoms in the last year

Number of climacteric stage women who were asked by the family doctor about climacteric symptoms in the last year/Total number of women in the sample × 100

2. Screening for overweight and obesity by calculating the body mass index (BMI) in the last year

Number of climacteric stage women who received overweight and obesity screening through the BMI calculation by the family doctor in the last year/Total number of women in the sample × 100

3. Screening for hypertension by measuring the systolic and diastolic blood pressure in the last year

Number of climacteric stage women that received hypertension screening through measuring the systolic and diastolic blood pressure by the family doctor or other health professionals, in the last year/Total number of women in the sample × 100

4. Screening for diabetes by measuring fasting plasma glucose in the last year

Number of climacteric stage women who received diabetes screening through fasting plasma glucose measurement, in the last year/Total number of women in the sample × 100

5. Screening for breast cancer through mammography in the last 2 years

Number of climacteric stage women who received breast cancer screening through mammography, in the last 2 years/Total number of women in the sample × 100

6. Screening for cervical cancer through Pap test in the last 3 years in women without a history of total hysterectomy

Number of climacteric stage women without a history of total hysterectomy for benign disease who received cervical cancer screening through Pap test, in the last 3 years/Total number of women in the sample without a history of total hysterectomy × 100

III. Treatment

1. Appropriate indication of oral hormone therapy (HT)

a) Number of women with moderate or severe vasomotor symptoms 7/day ≥ (at the time of the interview or the time to start oral HT) and without HT contraindications, who receive oral HT

b) Number of women with moderate or severe vasomotor symptoms <7/day(at the time of the interview or the time to start oral HT), or with mild symptoms or without vasomotor symptoms who do not receive oral HT/Total number of women in the sample × 100

2. Appropriate indication of vaginal HT

a) Number of women with moderate or severe vaginal atrophy symptoms and without oral HT who receive vaginal HT

b) the number of women without moderate to severe vaginal atrophy symptoms or with oral HT who do not receive vaginal HT/Total number of women in the sample × 100

3. Appropriate prescription of oral HT

Number of women receiving oral HT prescription appropriately according to the drug scheme, dose, schedule and duration of the treatment/Total number of women in the sample receiving oral HT × 100

4. Information on risks and benefits of oral HT

Number of women who were prescribed oral HT and who received information about its purpose, benefits and risks/Total number of women in the sample receiving oral HT × 100